— Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101 — BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 15, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the
BRISBANE, Calif. --(BUSINESS WIRE)--Sep. 26, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that President and CEO Jayson Dallas , M.D., will participate in a fireside chat at the Cantor Global
Wells Fargo Healthcare Conference , September 5 Baird Global Healthcare Conference , September 6 Bank of America Merrill Lynch Global Healthcare Conference , September 12 BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 29, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 8, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2018 .
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 7, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas , M.D., will give his first public presentation as the company’s President and CEO
— Experienced Leader Brings Extensive Record of Global Strategic and Commercial Operational Accomplishments and Successful Product Launches — BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 11, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for
— European APPEAL ( A llergy to P eanuts Im p acting E motions a nd L ife) Study Finds Peanut Allergy Has a Daily Impact on More than 80% of People with Peanut Allergy and Parents or Caregivers of Peanut-Allergic Minors — — Data Discussed at EAACI 2018 Reveal Uncertainty, Bullying and High Levels
— In U.S. Survey , Allergists Want Consensus in Oral Immunotherapy Terminology — — U.S. Allergists Preferred “Tolerated Dose” as the Most Clinically Relevant Term to Communicate Desensitization Levels to Oral Immunotherapy Patients — BRISBANE, Calif. & MUNICH, Germany --(BUSINESS WIRE)--May 29,
New analyses including adults enrolled in the Phase 3 PALISADE trial of AR101 show efficacy across the entire intent-to-treat population of peanut-allergic patients ages 4-55 New immunologic subset analyses show that AR101 treatment was linked to depletion of peanut-specific TH2A cells believed to
— Late-Breaking Oral Presentations on AR101 Phase 3 PALISADE Results in Peanut-Allergic Children and Adults and on European Study of Psychosocial Impact of Peanut Allergy — BRISBANE, Calif. --(BUSINESS WIRE)--May 15, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
